Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s
Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous system (CNS)-penetrant NLRP3 …
Post
-
-
Genomics to roll out predictive clinical test across UK
Oxford-based company Genomics is launching its Health Insights test across the UK, which will be used to predict and prevent …
-
AI-powered orchestration: Bringing the benefits to personalized therapy
Cell and gene therapies represent a groundbreaking advancement in medical science, offering transformative opportunities for treating complex and previously untreatable …
-
Clarametyx to advance trial of CMTX-101 with DMC approval
Clarametyx Biosciences has received approval from the Independent Data Monitoring Committee (DMC) to progress its Phase Ib/IIa trial of CMTX-101, an …
-
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment
The US Food and Drug Administration (FDA) has approved Ocugen’s investigational new drug (IND) amendment to initiate a Phase II/III …
-
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment
The US Food and Drug Administration (FDA) has approved Ocugen’s investigational new drug (IND) amendment to initiate a Phase II/III …
-
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
At the 2025 European Hematology Association (EHA) Congress, held from June 12 to June 15 in Milan, Italy, updated results …
-
Childhood traumatic events associated with endometriosis risk
According to the World Health Organization, endometriosis affects approximately one in ten women and girls of reproductive age globally. There …
-
US preterm and early term births increase between 2014 and 2023
A recent publication by the US Centers for Disease Control and Prevention (CDC) reports the trends of birth by gestational …
-
UK to expedite clinical trials with new health plan
The UK Government has announced its 10-Year Health Plan to expedite clinical trials and transform patient care with new treatments. The …
-
Astria shares initial outcomes from ongoing trial of navenibart for HAE
Astria Therapeutics has reported encouraging initial outcomes from its ongoing ALPHA-SOLAR trial of monoclonal antibody inhibitor of plasma kallikrein, navenibart …
-
EHA 2025: Genmab and AbbVie’s Epkinly outpaces BiTE rivals in r/r DLBCL trial
Relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) continues to present significant treatment challenges, particularly for patients who are …
-
EHA 2025: J&J’s dual-targeting bispecifics could redefine SOC for r/r MM
At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 to 15 June, the preliminary results …
-
Sarepta and Roche halt DMD gene therapy’s use after second death
Serepta and global partner Roche have discontinued the commercial and clinical use of Duchenne muscular dystrophy (DMD) gene therapy Elevidys …
-
J&J reports results from antibody combo trial for MM patients
Johnson & Johnson (J&J) has reported new outcomes from the Phase II RedirecTT-1 trial of bispecific antibodies, Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) …
